3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Polycythemia Vera
2
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Stem Cell Transplantation
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Biopsy
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
letermovir
1
itacitinib
1
iadademstat
1
demethoxycurcumin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
bomedemstat
×
90 days
×
Clear all
NCT06351631
2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3
Recruiting
400 enrolled